SCHEMBL17211756

SCHEMBL17211756

O=C(O)CCn1c(-c2ccccn2)ccc(C(=O)O)c1=O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.54
MAPT P10636 1/20 0.44
POLB P06746 1/20 0.43
FABP3 P05413 1/20 0.39
FABP4 P15090 1/20 0.39
FABP5 Q01469 1/20 0.39
KDM4E B2RXH2 4/20 0.39
HPGD P15428 2/20 0.39
ALDH1A1 P00352 2/20 0.39
APEX1 P27695 1/20 0.38
CNR2 P34972 1/20 0.38
KDM6B O15054 1/20 0.38
KDM4A O75164 1/20 0.38
KDM5C P41229 1/20 0.38
KDM4C Q9H3R0 1/20 0.38
KDM2A Q9Y2K7 1/20 0.38
KDM3A Q9Y4C1 1/20 0.38
CTSD P07339 1/20 0.38
HCAR2 Q8TDS4 1/20 0.37
HTT P42858 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17213442 0.90 L3MBTL1 (0.52) L3MBTL1MAPTPOLBFABP3FABP4
SCHEMBL17211686 0.90 L3MBTL1 (0.44) L3MBTL1KDM4EALDH1A1KDM6BKDM4A
SCHEMBL29626163 0.77 KDM4E (0.42) L3MBTL1KDM4EALDH1A1KDM6BKDM4A
SCHEMBL19377597 0.77 KDM4E (0.42) L3MBTL1KDM4EALDH1A1KDM6BKDM4A
SCHEMBL17211731 0.73 ALDH1A1 (0.64) L3MBTL1MAPTPOLBKDM4EHPGD
SCHEMBL17211683 0.69 KDM4E (0.56) L3MBTL1MAPTPOLBKDM4EHPGD
SCHEMBL28338537 0.67 KDM4E (0.53) L3MBTL1MAPTPOLBKDM4EALDH1A1
SCHEMBL30672122 0.67 GRM5 (0.40) KDM4EALDH1A1KDM6BKDM4AKDM5C
SCHEMBL19429626 0.65 FEN1 (0.39) L3MBTL1MAPTPOLBKDM4EHPGD
SCHEMBL24419436 0.65 NR1H4 (0.55) L3MBTL1MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2931280-B1 METHODS AND COMPOSITIONS FOR INHIBITING CNKSR1 PHUSIS THERAPEUTICS INC (US) 2018-02-14 EP disclosed
US-9340532-B2 Methods and compositions for inhibiting CNKSR1 PHUSIS THERAPEUTICS, INC. (US) 2016-05-17 US disclosed
US-9340532-B2 Methods and compositions for inhibiting CNKSR1 PHUSIS THERAPEUTICS, INC. (US) 2016-05-17 US disclosed
US-20150307482-A1 METHODS AND COMPOSITIONS FOR INHIBITING CNKSR1 PHUSIS THERAPEUTICS, INC. (US) 2015-10-29 US disclosed
US-20150307482-A1 METHODS AND COMPOSITIONS FOR INHIBITING CNKSR1 PHUSIS THERAPEUTICS, INC. (US) 2015-10-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150307482-A1 METHODS AND COMPOSITIONS FOR INHIBITING CNKSR1 CNKSR1, CAMKK1, CAMKK2 L3MBTL1 1932/4885MAPT 3576/4885POLB 3512/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.